Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
202 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dementia - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Dementia - Pipeline Review, H2 2015', provides an overview of the Dementia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Dementia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Dementia Overview 9 Therapeutics Development 10 Pipeline Products for Dementia - Overview 10 Pipeline Products for Dementia - Comparative Analysis 11 Dementia - Therapeutics under Development by Companies 12 Dementia - Therapeutics under Investigation by Universities/Institutes 16 Dementia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Dementia - Products under Development by Companies 21 Dementia - Products under Investigation by Universities/Institutes 25 Dementia - Companies Involved in Therapeutics Development 26 Adamas Pharmaceuticals, Inc. 26 Addex Therapeutics Ltd 27 Alector LLC 28 AlzProtect SAS 29 Apceth GmbH & Co. KG 30 BioArctic Neuroscience AB 31 Biogen, Inc. 32 Biotie Therapies Corp. 33 Chase Pharmaceuticals Corporation 34 Chronos Therapeutics Limited 35 Daewoong Pharmaceutical Co., Ltd. 36 Eisai Co., Ltd. 37 FORUM Pharmaceuticals Inc. 38 H. Lundbeck A/S 39 Hyundai Pharmaceutical Co., Ltd. 40 Ildong Pharmaceutical Co., Ltd. 41 IMMD Inc. 42 ImStar Therapeutics Inc. 43 Integrative Research Laboratories Sweden AB 44 Intellect Neurosciences, Inc. 45 Intra-Cellular Therapies, Inc. 46 MediPost Co., Ltd. 47 Neurimmune Holding AG 48 Neurodyn Inc. 49 Neuropore Therapies, Inc. 50 Oryzon Genomics S.A. 51 Otsuka Holdings Co., Ltd. 52 Pacific Northwest Biotechnology, LLC 53 Pivot Pharmaceuticals Inc 54 ProteoTech, Inc. 55 Sinil Pharmaceutical Co., Ltd 56 SK Chemicals Co., Ltd. 57 Stelic Institute & Co. 58 Sumitomo Dainippon Pharma Co., Ltd. 59 Sylentis S.A. 60 TauRx Therapeutics Ltd. 61 Tautatis Incorporated 62 Varinel, Inc. 63 WhanIn Pharmaceutical Co., Ltd. 64 Dementia - Therapeutics Assessment 65 Assessment by Monotherapy Products 65 Assessment by Combination Products 66 Assessment by Target 67 Assessment by Mechanism of Action 70 Assessment by Route of Administration 73 Assessment by Molecule Type 75 Drug Profiles 77 (memantine hydrochloride ER + donepezil hydrochloride) - Drug Profile 77 Antisense Oligonucleotides to Inhibit microRNA for Neurology - Drug Profile 78 Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 79 APC-621 - Drug Profile 80 aripiprazole - Drug Profile 81 AVCRI-104P3 - Drug Profile 83 AZP-2006 - Drug Profile 84 BAN-0805 - Drug Profile 86 brexpiprazole - Drug Profile 87 CB-2233 - Drug Profile 90 CB-8411 - Drug Profile 91 choline alfoscerate SR - Drug Profile 92 CPC-201 - Drug Profile 93 CPC-252 - Drug Profile 94 D-217 - Drug Profile 95 dehydroevodiamine hydrochloride - Drug Profile 96 dipraglurant IR - Drug Profile 97 Drugs for Dementia - Drug Profile 98 Drugs to Agonize c-MET for Dementia - Drug Profile 99 Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 100 DWJ-1365 - Drug Profile 101 E-2609 - Drug Profile 102 encenicline hydrochloride - Drug Profile 103 FRM-0334 - Drug Profile 106 GIBH-130 - Drug Profile 108 Gln-1062 - Drug Profile 109 GTC-6000 - Drug Profile 111 gugulipid - Drug Profile 112 HOB-075 - Drug Profile 113 IIPP-1 - Drug Profile 114 IMD-4482 - Drug Profile 115 IRL-752 - Drug Profile 116 ITI-007 - Drug Profile 117 KR-12 - Drug Profile 119 LUAF-20513 - Drug Profile 120 MM-201 - Drug Profile 121 Monoclonal Antibodies for Dementia and Alzheimer's Disease - Drug Profile 122 Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 123 NAT - Drug Profile 124 Neurostem - Drug Profile 125 NI-205 - Drug Profile 127 NI-308 - Drug Profile 128 NNC-269100 - Drug Profile 129 OG-635 - Drug Profile 130 OV-201 - Drug Profile 131 P-003 - Drug Profile 132 PD-61W3 - Drug Profile 133 Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 134 PST-900 - Drug Profile 135 RDC-5 - Drug Profile 136 SID-111 - Drug Profile 138 SIN-1502 - Drug Profile 139 Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 140 Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 141 Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 142 Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile 143 Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile 144 SYN-120 - Drug Profile 145 Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile 146 TAK-070 - Drug Profile 147 TauC-3 - Drug Profile 148 TPI-287 - Drug Profile 149 TRx-0237 - Drug Profile 151 TTT-3002 - Drug Profile 153 VAR-10100 - Drug Profile 154 WIB-1001C - Drug Profile 155 zonisamide - Drug Profile 156 Dementia - Recent Pipeline Updates 157 Dementia - Dormant Projects 183 Dementia - Discontinued Products 187 Dementia - Product Development Milestones 188 Featured News & Press Releases 188 Appendix 196 Methodology 196 Coverage 196 Secondary Research 196 Primary Research 196 Expert Panel Validation 196 Contact Us 196 Disclaimer 197
List of Tables
Number of Products under Development for Dementia, H2 2015 15 Number of Products under Development for Dementia - Comparative Analysis, H2 2015 16 Number of Products under Development by Companies, H2 2015 18 Number of Products under Development by Companies, H2 2015 (Contd..1) 19 Number of Products under Development by Companies, H2 2015 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2015 21 Comparative Analysis by Late Stage Development, H2 2015 22 Comparative Analysis by Clinical Stage Development, H2 2015 23 Comparative Analysis by Early Stage Development, H2 2015 24 Comparative Analysis by Unknown Stage Development, H2 2015 25 Products under Development by Companies, H2 2015 26 Products under Development by Companies, H2 2015 (Contd..1) 27 Products under Development by Companies, H2 2015 (Contd..2) 28 Products under Development by Companies, H2 2015 (Contd..3) 29 Products under Investigation by Universities/Institutes, H2 2015 30 Dementia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2015 31 Dementia - Pipeline by Addex Therapeutics Ltd, H2 2015 32 Dementia - Pipeline by Alector LLC, H2 2015 33 Dementia - Pipeline by AlzProtect SAS, H2 2015 34 Dementia - Pipeline by Apceth GmbH & Co. KG, H2 2015 35 Dementia - Pipeline by BioArctic Neuroscience AB, H2 2015 36 Dementia - Pipeline by Biogen, Inc., H2 2015 37 Dementia - Pipeline by Biotie Therapies Corp., H2 2015 38 Dementia - Pipeline by Chase Pharmaceuticals Corporation, H2 2015 39 Dementia - Pipeline by Chronos Therapeutics Limited, H2 2015 40 Dementia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 41 Dementia - Pipeline by Eisai Co., Ltd., H2 2015 42 Dementia - Pipeline by FORUM Pharmaceuticals Inc., H2 2015 43 Dementia - Pipeline by H. Lundbeck A/S, H2 2015 44 Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015 45 Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015 46 Dementia - Pipeline by IMMD Inc., H2 2015 47 Dementia - Pipeline by ImStar Therapeutics Inc., H2 2015 48 Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2015 49 Dementia - Pipeline by Intellect Neurosciences, Inc., H2 2015 50 Dementia - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 51 Dementia - Pipeline by MediPost Co., Ltd., H2 2015 52 Dementia - Pipeline by Neurimmune Holding AG, H2 2015 53 Dementia - Pipeline by Neurodyn Inc., H2 2015 54 Dementia - Pipeline by Neuropore Therapies, Inc., H2 2015 55 Dementia - Pipeline by Oryzon Genomics S.A., H2 2015 56 Dementia - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 57 Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2015 58 Dementia - Pipeline by Pivot Pharmaceuticals Inc, H2 2015 59 Dementia - Pipeline by ProteoTech, Inc., H2 2015 60 Dementia - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2015 61 Dementia - Pipeline by SK Chemicals Co., Ltd., H2 2015 62 Dementia - Pipeline by Stelic Institute & Co., H2 2015 63 Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 64 Dementia - Pipeline by Sylentis S.A., H2 2015 65 Dementia - Pipeline by TauRx Therapeutics Ltd., H2 2015 66 Dementia - Pipeline by Tautatis Incorporated, H2 2015 67 Dementia - Pipeline by Varinel, Inc., H2 2015 68 Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2015 69 Assessment by Monotherapy Products, H2 2015 70 Assessment by Combination Products, H2 2015 71 Number of Products by Stage and Target, H2 2015 73 Number of Products by Stage and Mechanism of Action, H2 2015 76 Number of Products by Stage and Route of Administration, H2 2015 79 Number of Products by Stage and Molecule Type, H2 2015 81 Dementia Therapeutics - Recent Pipeline Updates, H2 2015 162 Dementia - Dormant Projects, H2 2015 188 Dementia - Dormant Projects (Contd..1), H2 2015 189 Dementia - Dormant Projects (Contd..2), H2 2015 190 Dementia - Dormant Projects (Contd..3), H2 2015 191 Dementia - Discontinued Products, H2 2015 192
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
